PATHOGENESIS OF HEPATIC COMA
肝昏迷的发病机制
基本信息
- 批准号:3225648
- 负责人:
- 金额:$ 31.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1991
- 资助国家:美国
- 起止时间:1991-09-30 至 1995-08-31
- 项目状态:已结题
- 来源:
- 关键词:6 phosphofructokinase acute disease /disorder alpha ketoglutarate aminoacid metabolism aspartate astrocytes bioenergetics brain metabolism cellular pathology chronic disease /disorder enzyme inhibitors enzyme mechanism glutamate dehydrogenase glutathione hepatic coma /encephalopathy hepatotoxin high performance liquid chromatography laboratory mouse laboratory rat liver failure liver function malates medical complication neurotransmitter metabolism nitrogen balance pathologic process radiotracer tissue /cell culture urea cycle
项目摘要
The underlying assumption of the proposed research is that excess
ammonia is a major factor in the neurological complications arising from
both acute and chronic liver disease. Failure of the diseased liver to
remove ammonia from the portal circulation, and limited capacity of
extrahepatic tissues to remove this ammonia, leads to an increase in
ammonia entering the brain. Our hypothesis is that the increased
ammonia load leads to a disruption of cerebral energy metabolism by
interfering with, a) the malate-aspartate shuttle (MAS) for the
transport of reducing equivalent between cytosol and mitochondria and
with b) the TCA cycle (at the level of alpha-ketoglutarate dehydrogenase
complex and, possibly, at other dehydrogenase steps). Prolonged
exposure to excess ammonia results in increased cerebral "sensitivity"
to ammonia, hypoxia, and other superimposed metabolic stresses.
Astrocytes in the brains of liver diseased patients and in the brains of
animals subjected to experimentally-induced metabolic impairment. To
evaluate the role of ammonia in the pathogenesis of hepatic
encephalopathy our goals will be multifaceted: 1) to design inhibitors
of aspartate aminotransferase (an important component of the MAS) that
will cross the blood-brain barrier, in order to investigate the
metabolic consequences of disruption of the MAS; 2) to use [13N]
leucine, [13N] tyrosine, [13N-amine'- and [13N-amide]glutamine (13N,
positron emitter; t 1/2=9.96 min.) to label the astrocytic pool in vivo,
to provide evidence that astrocytic glutamine is a precursor of neuronal
GABA and to determine whether this pathway is disrupted in the
hyperammonemic animal; 3) to elucidate the role of glutathione in the
normal and hyperammonemic rat brain; 4) to determine the major source of
metabolically-derived ammonia in brain (glutaminase, glutamate
dehydrogenase, and/or the purine nucleotide cycle). Finally, some
workers have questioned the notion that the major role of the urea cycle
is to remove excess nitrogen and have suggested that the urea cycle may
have evolved to regulate acid-base levels. To provide evidence for, or
against, this theory we will use our recently developed tracer
techniques to investigate the short-term metabolic fate of 13N labeled
ammonia, alanine and glutamate in the metabolically acidotic rat. The
urea cycle is compromised in liver disease. Therefore, it is important
to understand how the disruption of this cycle affects both whole-body
nitrogen homeostasis and acid-base balance in liver disease. It is
hoped that the results of the above mentioned studies will lead to
improved therapies in patients with liver disease.
这项拟议研究的基本假设是
氨是引起神经并发症的一个主要因素
包括急性和慢性肝病。病肝不能
从门静脉循环中去除氨,并限制容量
肝外组织来清除这种氨,导致增加
氨进入大脑。我们的假设是,增加的
氨负荷通过以下方式导致大脑能量代谢紊乱
干扰,a)苹果酸-天冬氨酸穿梭(MAS)
还原当量在细胞质和线粒体之间的转运
B)三氯乙酸循环(在α-酮戊二酸脱氢酶水平上
复杂的,并且可能在其他脱氢酶步骤中)。延长了
暴露在过量氨中会增加大脑的“敏感度”
氨、低氧和其他叠加的代谢压力。
肝病患者脑内星形胶质细胞和大鼠脑内星形胶质细胞
遭受实验诱导的代谢损伤的动物。至
评价氨在肝病发病机制中的作用
脑病我们的目标将是多方面的:1)设计抑制剂
天冬氨酸氨基转移酶(MAS的重要组成部分)
将穿越血脑屏障,以调查
MAS中断的代谢后果;2)使用[13N]
亮氨酸、[13N]酪氨酸、[13N-胺‘-和[13N-酰胺]谷氨酰胺(13N,
正电子发射器;t1/2=9.96分钟。)为了标记活体内的星形细胞池,
提供证据证明星形细胞谷氨酰胺是神经细胞的前体
并确定这一途径是否在
3)阐明谷胱甘肽在高氨血症动物模型中的作用。
正常和高氨血症大鼠脑;4)确定其主要来源
大脑中的代谢性氨(谷氨酰胺酶、谷氨酸
脱氢酶和/或嘌呤核苷酸循环)。最后,一些
工人们质疑尿素循环的主要作用
是去除多余的氮,并提出尿素循环可能
已经进化到调节酸碱水平。为…提供证据,或
反对这一理论,我们将使用我们最近开发的示踪剂
~(13)N标记的短期代谢去向研究技术
代谢性酸中毒大鼠的氨、丙氨酸和谷氨酸。这个
尿素循环在肝病中受到损害。因此,重要的是
为了了解这一周期的中断如何影响全身
肝病中的氮素平衡和酸碱平衡。它是
希望上述研究的结果将导致
改善肝病患者的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Arthur Joseph Cooper其他文献
Arthur Joseph Cooper的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Arthur Joseph Cooper', 18)}}的其他基金
ROLE OF TRANSGLUTAMINASES IN NEURODEGENERATIVE DISEASES
转谷氨酰胺酶在神经退行性疾病中的作用
- 批准号:
6926910 - 财政年份:2005
- 资助金额:
$ 31.76万 - 项目类别:
Mechanism of Glutathione Conjugate Dependent Toxicity
谷胱甘肽缀合物依赖性毒性机制
- 批准号:
6805315 - 财政年份:1997
- 资助金额:
$ 31.76万 - 项目类别:
MECHANISM OF GLUTATHIONE CONJUGATE DEPENDENT TOXICITY
谷胱甘肽结合物依赖性毒性机制
- 批准号:
2749706 - 财政年份:1997
- 资助金额:
$ 31.76万 - 项目类别:
MECHANISM OF GLUTATHIONE CONJUGATE DEPENDENT TOXICITY
谷胱甘肽结合物依赖性毒性机制
- 批准号:
6043502 - 财政年份:1997
- 资助金额:
$ 31.76万 - 项目类别:
Mechanism of Glutathione Conjugate Dependent Toxicity
谷胱甘肽缀合物依赖性毒性机制
- 批准号:
6929839 - 财政年份:1997
- 资助金额:
$ 31.76万 - 项目类别:
Mechanism of Glutathione Conjugate Dependent Toxicity
谷胱甘肽缀合物依赖性毒性机制
- 批准号:
7101884 - 财政年份:1997
- 资助金额:
$ 31.76万 - 项目类别:
Mechanism of Glutathione Conjugate Dependent Toxicity
谷胱甘肽缀合物依赖性毒性机制
- 批准号:
7532866 - 财政年份:1997
- 资助金额:
$ 31.76万 - 项目类别:
MECHANISM OF GLUTATHIONE CONJUGATE DEPENDENT TOXICITY
谷胱甘肽结合物依赖性毒性机制
- 批准号:
6178519 - 财政年份:1997
- 资助金额:
$ 31.76万 - 项目类别:
Mechanism of Glutathione Conjugate Dependent Toxicity
谷胱甘肽缀合物依赖性毒性机制
- 批准号:
6729472 - 财政年份:1997
- 资助金额:
$ 31.76万 - 项目类别:
MECHANISM OF GLUTATHIONE CONJUGATE DEPENDENT TOXICITY
谷胱甘肽结合物依赖性毒性机制
- 批准号:
2720950 - 财政年份:1997
- 资助金额:
$ 31.76万 - 项目类别:














{{item.name}}会员




